PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

To Validate, Develop and Implement The Scope of Medical Care for Metastatic, Persistent and Recurrent Cervical Cancer Using The Method of Chemoimmunotargeted Therapy

This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.

Inclusion Criteria:

• Age ≥18-≤75 years.

• Histologically confirmed diagnosis.

• One of the forms of the cervical cancer:

  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).

• Availability of material for determining PD-L-1 expression for immunotherapy candidates.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• No contraindications to chemotherapy, immunotherapy, or bevacizumab.

• Signed informed consent to participate in the study.

Exclusion Criteria:

• Presence of another active malignant invasive neoplasm.
• Pregnancy or lactation period.